Pfizer Talks Potential Spinout, Suggests Tax-Inversion Play Still Possible
This article was originally published in The Pink Sheet Daily
Executive Summary
With 10 months of profit-and-loss data from its division into innovative and established product units, Pfizer will continue considering whether a spin-out into two separate companies offers shareholders the best value, CEO Read tells quarterly call. He also said tax-inversion remains a viable strategy for the pharma.